Yun J Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3811084/publications.pdf Version: 2024-02-01



VIIN I KIM

#	Article	IF	CITATIONS
1	Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology, 1998, 51, 850-855.	1.1	608
2	Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 12784-12789.	7.1	341
3	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study. Lancet Neurology, The, 2011, 10, 898-908.	10.2	294
4	Huntingtin Is Present in the Nucleus, Interacts with the Transcriptional Corepressor C-terminal Binding Protein, and Represses Transcription. Journal of Biological Chemistry, 2002, 277, 7466-7476.	3.4	240
5	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Movement Disorders, 2002, 17, 303-312.	3.9	183
6	Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus. Brain, 1999, 122, 1919-1931.	7.6	152
7	Human-to-mouse prion-like propagation of mutant huntingtin protein. Acta Neuropathologica, 2016, 132, 577-592.	7.7	145
8	Huntingtin Associates with Acidic Phospholipids at the Plasma Membrane. Journal of Biological Chemistry, 2005, 280, 36464-36473.	3.4	133
9	Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics, 2008, 9, 263-269.	1.4	105
10	SPECT imaging of pre- and postsynaptic dopaminergic alterations in <scp> </scp> -dopa–untreated PD. Neurology, 1999, 52, 1206-1206.	1.1	102
11	Historical and Clinical Features of Psychogenic Tremor: a Review of 70 Cases. Canadian Journal of Neurological Sciences, 1999, 26, 190-195.	0.5	99
12	A Validation Study of a Smartphone-Based Finger Tapping Application for Quantitative Assessment of Bradykinesia in Parkinson's Disease. PLoS ONE, 2016, 11, e0158852.	2.5	91
13	Gray and white matter changes linking cerebral small vessel disease to gait disturbances. Neurology, 2016, 86, 1199-1207.	1.1	75
14	Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Neurobiology of Disease, 2006, 22, 346-356.	4.4	64
15	Genetics of Progressive Supranuclear Palsy. Journal of Movement Disorders, 2015, 8, 122-129.	1.3	60
16	Klotho is a genetic risk factor for ischemic stroke caused by cardioembolism in Korean females. Neuroscience Letters, 2006, 407, 189-194.	2.1	59
17	Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1250-1252.	1.9	57
18	Association of mutations in the glucocerebrosidase gene with Parkinson disease in a Korean population. Neuroscience Letters, 2012, 514, 12-15.	2.1	49

Yun J Kim

#	Article	IF	CITATIONS
19	PINK1 positively regulates HDAC3 to suppress dopaminergic neuronal cell death. Human Molecular Genetics, 2015, 24, 1127-1141.	2.9	38
20	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiology of Aging, 2014, 35, 266.e5-266.e14.	3.1	36
21	White matter microstructural changes in pure Alzheimer's disease and subcortical vascular dementia. European Journal of Neurology, 2015, 22, 709-716.	3.3	34
22	Huntingtin is degraded to small fragments by calpain after ischemic injuryâ~†. Experimental Neurology, 2003, 183, 109-115.	4.1	32
23	Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnosed Parkinson Disease. Neurology, 2021, 96, e2121-e2131.	1.1	32
24	Validation of the Korean Version of the Scale for Outcomes in Parkinson's Disease-Autonomic. Journal of Movement Disorders, 2017, 10, 29-34.	1.3	32
25	Utility of the Midbrain Tegmentum Diameter in the Differential Diagnosis of Progressive Supranuclear		

Yun J Кім

#	Article	IF	CITATIONS
37	Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson's disease. PLoS ONE, 2021, 16, e0247354.	2.5	21
38	Clinical Heterogeneity of Atypical Pantothenate Kinase-Associated Neurodegeneration in Koreans. Journal of Movement Disorders, 2016, 9, 20-27.	1.3	21
39	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	2.8	21
40	Sequence variants of ACE, AGT, AT1R, and PAI-1 as genetic risk factors for vascular dementia. Neuroscience Letters, 2006, 401, 276-279.	2.1	20
41	Dura Mater Graft-Associated Creutzfeldt-Jakob Disease: The First Case in Korea. Journal of Korean Medical Science, 2011, 26, 1515.	2.5	20
42	Midbrain atrophy in subcortical ischemic vascular dementia. Journal of Neurology, 2009, 256, 1997-2002.	3.6	18
43	Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease. Movement Disorders, 2017, 32, 1211-1220.	3.9	17
44	Diabetes mellitus and drug-induced parkinsonism: A case–control study. Journal of the Neurological Sciences, 2009, 284, 140-143.	0.6	16
45	SCA in Korea and its regional distribution: A multicenter analysis. Parkinsonism and Related Disorders, 2011, 17, 72-75.	2.2	16
46	Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with Parkinson's disease. Journal of Clinical Neuroscience, 2017, 36, 108-113.	1.5	16
47	Cognitive Dysfunction in Drug-induced Parkinsonism Caused by Prokinetics and Antiemetics. Journal of Korean Medical Science, 2015, 30, 1328.	2.5	15
48	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	3.9	15
49	Alphaâ€synuclein repeat variants and survival in Parkinson's disease. Movement Disorders, 2014, 29, 1053-1057.	3.9	14
50	Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 271-276.	1.9	14
51	A Visual Rating Scale for the Hummingbird Sign with Adjustable Diagnostic Validity. Journal of Parkinson's Disease, 2015, 5, 605-612.	2.8	13
52	Evidence of Inflammation in Parkinson's Disease and Its Contribution to Synucleinopathy. Journal of Movement Disorders, 2022, 15, 1-14.	1.3	12
53	Temporal Evolution of Inflammation and Neurodegeneration With Alpha-Synuclein Propagation in Parkinson's Disease Mouse Model. Frontiers in Integrative Neuroscience, 2021, 15, 715190.	2.1	12

Analysis of Dosage Mutation in PARK2 among Korean Patients with Early-Onset or Familial Parkinson's

Үим Ј Кім

#	Article	IF	CITATIONS
55	Apolipoprotein E4 Affects Topographical Changes in Hippocampal and Cortical Atrophy in Alzheimer's Disease Dementia: A Five-Year Longitudinal Study. Journal of Alzheimer's Disease, 2015, 44, 1075-1085.	2.6	11
56	Meta-Analysis of Differentially Expressed Genes in the Substantia Nigra in Parkinson's Disease Supports Phenotype-Specific Transcriptome Changes. Frontiers in Neuroscience, 2020, 14, 596105.	2.8	11
57	Automatic, Qualitative Scoring of the Interlocking Pentagon Drawing Test (PDT) Based on U-Net and Mobile Sensor Data. Sensors, 2020, 20, 1283.	3.8	11
58	Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease. Neurology, 2019, 93, e665-e674.	1.1	10
59	Trends in the Prevalence of Drug-Induced Parkinsonism in Korea. Yonsei Medical Journal, 2019, 60, 760.	2.2	10
60	An Autopsy Proven Case of CSF1R-mutant Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) with Premature Ovarian Failure. Experimental Neurobiology, 2019, 28, 119-129.	1.6	10
61	REM sleep behavior disorder in early Parkinson's disease predicts the rapid dopaminergic denervation. Parkinsonism and Related Disorders, 2020, 80, 120-126.	2.2	10
62	Alteration of the corpus callosum in patients with Alzheimer's disease: Deep learning-based assessment. PLoS ONE, 2021, 16, e0259051.	2.5	9
63	A Case of Painful Hemimasticatory Spasm with Masseter Muscle Hypertrophy Responsive to Botulinum Toxin. Journal of Movement Disorders, 2009, 2, 95-97.	1.3	8
64	Long-term prognosis of symptomatic isolated middle cerebral artery disease in Korean stroke patients. BMC Neurology, 2011, 11, 138.	1.8	8
65	Corticobasal syndrome associated with antiphospholipid syndrome without cerebral infarction. Neurology, 2014, 82, 730-731.	1.1	8
66	Correlating Parkinson's disease motor symptoms with three-dimensional [18F]FP-CIT PET. Japanese Journal of Radiology, 2015, 33, 609-618.	2.4	8
67	Preferential microglial activation associated with pathological alpha synuclein transmission. Journal of Clinical Neuroscience, 2020, 81, 469-476.	1.5	8
68	Subtypes of Sleep Disturbance in Parkinson's Disease Based on the Cross-Culturally Validated Korean		

Yun J Кім

#	Article	IF	CITATIONS
73	Validation of the Korean Version of the Scales for Outcomes in Parkinson's Disease-Sleep. Journal of Korean Medical Science, 2018, 33, e14.	2.5	5
74	Temporalis Muscle Thickness as an Indicator of Sarcopenia Is Associated With Long-term Motor Outcomes in Parkinson's Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2242-2248.	3.6	5
75	Normal Diffusion-Weighted MRI During the Acute Stage of Central Pontine Myelinolysis. International Journal of Neuroscience, 2012, 122, 477-479.	1.6	4
76	Asymmetrical changes of the pedunculopontine nucleus in a case of freezing of gait after carbon monoxide intoxication. Clinical Neurology and Neurosurgery, 2014, 125, 15-18.	1.4	4
77	Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in		